Waylis Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for WAYLIS THERAP, and when can generic versions of WAYLIS THERAP drugs launch?
WAYLIS THERAP has eleven approved drugs.
There is one US patent protecting WAYLIS THERAP drugs.
There are twenty-four patent family members on WAYLIS THERAP drugs in fourteen countries and five supplementary protection certificates in four countries.
Summary for Waylis Therap
| International Patents: | 24 |
| US Patents: | 1 |
| Tradenames: | 11 |
| Ingredients: | 11 |
| NDAs: | 11 |
Drugs and US Patents for Waylis Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Waylis Therap | COREG | carvedilol | TABLET;ORAL | 020297-004 | May 29, 1997 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Waylis Therap | ACIPHEX | rabeprazole sodium | TABLET, DELAYED RELEASE;ORAL | 020973-002 | Aug 19, 1999 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| Waylis Therap | FLUTAMIDE | flutamide | CAPSULE;ORAL | 075298-001 | Sep 18, 2001 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Waylis Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-001 | Dec 15, 2004 | 6,864,257*PED | ⤷ Sign Up |
| Waylis Therap | COREG | carvedilol | TABLET;ORAL | 020297-003 | Sep 14, 1995 | 4,503,067*PED | ⤷ Sign Up |
| Waylis Therap | LUNESTA | eszopiclone | TABLET;ORAL | 021476-001 | Dec 15, 2004 | 6,319,926*PED | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for WAYLIS THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-12-21 |
| ➤ Subscribe | Capsules | 0.5 mg | ➤ Subscribe | 2007-10-29 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg and 3 mg | ➤ Subscribe | 2008-12-15 |
| ➤ Subscribe | Extended-release Capsules | 10 mg and 20 mg | ➤ Subscribe | 2008-03-18 |
| ➤ Subscribe | Extended-release Capsules | 80 mg | ➤ Subscribe | 2007-11-19 |
| ➤ Subscribe | Capsule | 0.5 mg/0.4 mg | ➤ Subscribe | 2010-10-26 |
International Patents for Waylis Therap Drugs
Supplementary Protection Certificates for Waylis Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0268956 | 1999C0030 | Belgium | ⤷ Sign Up | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
| 0719278 | SPC/GB03/018 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117 |
| 0719278 | 23/2003 | Austria | ⤷ Sign Up | PRODUCT NAME: DUTASTERIDE, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SOLVATES; NAT. REGISTRATION NO/DATE: 1-24844, 1-24845 20030217; FIRST REGISTRATION: SE 17871, 17872 20020719 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
